# Essai Clinique

Généré le 09 mai 2025 à partir de

| | |
|---|---|
| Titre | A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) With ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD) |
| Protocole ID | CTTC 1901 |
| ClinicalTrials.gov ID | NCT04202835 |
| Type(s) de cancer | Leucémie myéloïde aiguë (LMA) |
| Phase | Phase II |
| Type étude | Autre |
| Institution | CHU DE QUEBEC – UNIVERSITE LAVAL<br>HOPITAL DE L'ENFANT-JESUS<br>1401 18e Rue, Québec, QC, G1J 1Z4 |
| Ville | |
| Investigateur principal | Dre Geneviève Gallagher |
| Coordonnateur | Philippe Nadeau<br>418-649-0252 poste 63115 |
| Statut | Fermé |
| But étude | A Randomized Pilot Trial to test the feasibility of comparing anti-thymocyte globulin plus post transplant cyclophosphamide with anti-thymocyte globulin alone to prevent chronic graft versus host disease. |
| Critères d'éligibilité | 1. The participant is aged between 16 and 70<br>2. The participant has either<br>  1. Acute myeloid leukemia in remission, or<br>  2. Myelodysplastic syndrome<br>3. The participant will receive a Hematopoietic Progenitor Cell graft obtained by apheresis ("HPC, Apheresis")<br>4. The participant has a related or unrelated donor, who is fully Major Histocompatibility Complex (MHC)-matched with the recipient at Human Leukocyte Antigen (HLA)-A, B, C and DRB1.<br>5. The participant meets the transplant centre's criteria for transplantation, using either myeloablative or non-myeloablative or reduced intensity conditioning .<br>6. The participant has good performance status (Karnofsky ≥60%)<br>7. The participant is able to understand and sign the informed consent form<br>8. Ability and willingness to comply with study procedures and schedule, in the Investigator's opinion. |
| Critères d'exclusion | 1. The participant is HIV antibody positive<br>2. The participant has a hypersensitivity to rabbit proteins or Thymoglobulin® pharmaceutical excipients, glycine or mannitol<br>3. The participant has active or chronic infection (i.e. infection requiring oral or IV therapy)<br>4. The participant (if female and of childbearing potential) is pregnant or breast-feeding at the time of enrollment<br>5. The participant (if female and of childbearing potential) does not agree to use an adequate contraceptive method from the time of enrollment until a minimum of one year following transplant<br>6. The participant (if male and fertile) does not agree to use an adequate contraceptive method from the time of enrollment until a minimum of one year following transplant.<br>7. The participant has Mixed Phenotype Acute Leukemia. |